==== Front Sci Rep Sci Rep Scientific Reports 2045-2322 Nature Publishing Group UK London 78125 10.1038/s41598-020-78125-4 Article Single nucleotide vitamin D receptor polymorphisms (FokI, BsmI, ApaI, and TaqI) in the pathogenesis of prematurity complications Kosik Katarzyna 1 Szpecht Dawid dawid.szpecht@poczta.fm 1 Al-Saad Salwan R. 2 Karbowski Lukasz M. 2 Kurzawińska Grażyna 3 Szymankiewicz Marta 1 Drews Krzysztof 3 Wolski Hubert 3 Seremak-Mrozikiewicz Agnieszka 3 1 grid.22254.330000 0001 2205 0971Chair and Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland 2 grid.22254.330000 0001 2205 0971Poznan University of Medical Sciences, Poznan, Poland 3 grid.22254.330000 0001 2205 0971Department of Perinatology and Women’s Diseases, Poznan University of Medical Sciences, Poznan, Poland 3 12 2020 3 12 2020 2020 10 2109825 9 2020 17 11 2020 © The Author(s) 2020Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.The vitamin D receptor (VDR), coded by the VDR gene, plays a pivotal role in executing cellular functions when bound by the active form of vitamin D. Gene polymorphisms in this receptor have been increasingly associated with a heightened state of vulnerability to certain diseases. However, limited data is available concerning the role of VDR gene polymorphisms in preterm infant complications. In 114 premature infants (< 32 weeks gestation) we analyze four single nucleotide VDR polymorphisms (rs2228570 (FokI), rs1544410 (BsmI), rs797532 (ApaI), rs731236 (TaqI)) for their association with respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC) and retinopathy of prematurity (ROP). The results show that BPD was almost four times more likely in infants with the genotype CC of ApaI (rs7975232) (OR 3.845; p = 0.038). While both BPD and NEC were 2.1 times more likely to occur in preterm infants with the allele C of ApaI (rs7975232) (respectively: OR 2.111 and OR 2.129, p < 0.05). The ApaI VDR polymorphism appears to influence incidence of BPD and NEC in preterm infants. Considering VDR polymorphisms in future genetic investigations, in preterm complications, may prove clinically relevant. Subject terms DiseasesMolecular medicinePathogenesisRisk factorsissue-copyright-statement© The Author(s) 2020 ==== Body Introduction Vitamin D activity is regulated by the vitamin D receptor (VDR), also known as the calcitriol receptor or Nr1I1. It is a nuclear transcription factor that, when activated by a ligand, modulates gene expression1. VDR is expressed extensively in immune system cells, thymus, placenta, alveolar type-II cells, osteoblasts, chondrocytes, and skin epithelium2,3. In contrast to the later, erythrocytes, mature striated muscle cells, and highly differentiated neural cells of the cerebral cortex present considerably less vitamin D receptors4. In the human body, most of the utilized vitamin D is sourced by endogenous cutaneous production. Pre-vitamin D is provided by photoisomerization from 7-dehydrocholesterol (ergosterol) due to ultraviolet radiation (UV-B). Then, it is transformed to cholecalciferol, and after hydroxylation in the liver and kidneys—to calcitriol. This active hormonal form binds to the vitamin D binding protein (VDBP) in the blood and reaches the target cell. Once it enters the cell, it attaches to VDR in the cytoplasm and constructs a combined complex. This fusion enters the nucleus, where it heterodimerizes with retinoic acid X receptor and enhances vitamin D-dependent gene transcription5. The resulting interactions trigger the tissue-specific responses and their molecularly correlated cascading effects. As with many types of receptors, the genes responsible for coding the VDR present with subtle allelic variants located on chromosome 126. To date, the most explored VDR polymorphisms are rs2228570 (FokI), rs1544410 (BsmI), rs797532 (ApaI), rs731236 (TaqI)7. TaqI and FokI consist of a single nucleotide change—A to G and G to A in exons 9 and 2, respectively. Whilst BsmI and ApaI are located in intron 8 and result in a change from G to A and A to C, respectively. Possible associations are being explored between VDR gene variation and the development of different types of cancers (ApaI polymorphism in the VDR gene may prove to be a good marker for the use of individualized chemotherapy in the treatment of non-small cell lung carcinoma)8, autoimmune diseases (risk of developing multiple sclerosis is still being investigated)9, diabetes10,11, asthma12, cardiovascular diseases13, osteoporosis14, and susceptibility to infection15. The following work is centred to investigate VDR polymorphisms (FokI, BsmI, ApaI, TaqI) and their association with risk for neonatal complications such as respiratory distress syndrome, intraventricular hemorrhage, bronchopulmonary dysplasia, necrotizing enterocolitis and retinopathy of prematurity. Material and methods Study population The study comprises a population of 114 premature infants born within 22 + 6 to 32 + 0 weeks of gestation, between the years 2014 and 2019. All infants were hospitalized at the Department of Neonatology (III Level Hospital) located in the Clinical Hospital of Gynecology and Obstetrics at Poznan University of Medical Sciences in Poznan, Poland. Homogenic consistency was maintained as a result of all infants being of Caucasian origin. Excluded were neonates born after 32 + 0 weeks of pregnancy, multiple pregnancy births, infants with chromosomal abnormalities, TORCH infections (rubella, herpes, cytomegalovirus, toxoplasmosis, etc.) and infants without antenatal steroid therapy. Clinical features Clinical factors were observed for association with VDR gene polymorphism and its influence on neonatal development and preterm complications. The clinical features include: gender, gestational age (GA; weeks), birth weight (BW, grams), mode of delivery (vaginal birth vs cesarean section), APGAR score in 1st and 5th minute, and pH and blood base excess (BE) in cord blood. The five preterm complications evaluated were respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC) and retinopathy of prematurity (ROP). Infants who were delivered outside third-level hospitals were also analyzed for developing complications of preterm birth. Diagnosis RDS The diagnosis of RDS is based on a clinical picture of a preterm infant with the onset of progressive respiratory failure shortly after birth16. This is manifested by breathing disorders and an increase in the oxygen requirement, in conjunction with a characteristic chest radiograph or ultrasound (4–15 MHz transducer, MyLabEight, Esaote). Criteria for the classification of RDS was obtained from European Consensus Guidelines on the Management of Respiratory Distress Syndrome17. IVH Intraventricular hemorrhage was diagnosed with the use of cranial ultrasound (10 MHz transducer, Prosundα7 Premier or Aloka; 4–15 MHz transducer, MyLabEight, Esaote). Routine cranial ultrasound screenings were performed on the 1st, 3rd and 7th days post birth in accordance with the local hospital standards. Classification of IVH was obtained using criteria based on the Papile IVH Severity Scale18. BPD Bronchopulmonary dysplasia was defined as the need for at least one form of oxygen supplementation either at 28 postnatal days or 36 weeks postmenstrual age (PMA)19. Notably, this definition does not take into account the severity of respiratory disease or extent of prematurity20–22. NEC Necrotizing enterocolitis is characterized by ischemic necrosis of the intestinal mucosa, which is associated with severe inflammation, invasion of enteric gas forming organisms, and dissection of gas into the bowel wall and portal venous system23. Severity of NEC can vary in degree in preterm neonates and can manifest in variable stages. Diagnosis of NEC was based of the Modified Bell’s clinical criteria assessment of NEC stages using an abdomen ultrasound (5–8 and 13 MHz transducer, Prosundα7 Premier, Aloka or 4–15 MHz transducer, MyLabEight, Esaote) and an X-Ray of the abdomen24. Within the Modified Bell’s clinical criteria, stages were divided into three specific components for the most accurate recognition and diagnosis of NEC25. ROP Retinopathy of prematurity is classified as a developmental vascular proliferative disorder that occurs in the retina of preterm infants with incomplete retinal vascularization. The screening examination followed the guidelines of Polish Ophthalmological Society for ROP screening (≤ 33 weeks of postmenstrual age, ≤ 1800 g of birth weight or if they were determined to be at high risk by a neonatologist)26. Patients were examined with binocular indirect ophthalmoscopy by a team of three trained paediatric ophthalmologists specializing in ROP. The initial fundus examination was performed 4 weeks postnatally, with further follow-up every 7–10 days until full vascularization of the retina, stabilization of the changes or the necessity for treatment. Findings were classified according to the Revisited International Classification of Retinopathy of Prematurity (ICROP)27,28. Studied polymorphisms The criteria for selections of candidate genes in the present study were their potential involvement in the pathogenesis of RDS, IVH, NEC, BPD or ROP. We studied 4 single nucleotide polymorphisms of vitamin D receptor: rs2228570 (FokI), rs1544410 (BsmI), rs797532 (ApaI), rs731236 (TaqI). A sample of blood was taken following birth, after admission to the intensive care unit. Genomic DNA was extracted from blood leukocytes using QIAamp DNA Blood Mini Kit (QIAGEN Inc; Germany). Genotyping was performed using polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP) procedures. For detection of rs2228570 mutation PCR was amplified with starters: 5′-AGCTGGCCCTGGCACTGACTCTGCTCT-3′, 5′-ATGGAAACACCTTGCTTCTTCTCCCTC-3′ (PCR product 267 bp long) and hydrolyzed at 37 °C with FokI restriction enzyme (Eurx, Poland). The following genotypes were obtained: CC (FF) 267 bp; CT (Ff) 267, 197, 70 bp and TT (ff) 197, 70 bp. For detection of the rs1544410 mutation, PCR was amplified with starters: 5′-CAACCAAGACTACAAGTACCGCGTCAGTGA-3′, 5′-AACCAGCGGGAAGAGGTCAAGGG-3′ (PCR product 821 bp long) and hydrolyzed at 37 °C with Mva12691 (BsmI) restriction enzyme (Thermo Scientific, USA). The following genotypes were obtained: GG (bb) 646, 175 bp; GA (Bb) 821, 646,175 bp; AA (BB) 821 bp. The rs7975232 and rs731236 polymorphic sites of the VDR gene were detected using starters: 5′-CAGAGCATGGACAGGGAGCAA-3′, 5′-GCAACTCCTCATGGCTGAGGTCTC-3′. PCR product (745 bp long) was hydrolyzed with ApaI restriction enzyme at 25 °C overnight (Eurx, Poland) and found the following genotypes: AA (AA) 745 bp; AC (Aa) 745, 528, 217 bp and CC (aa) 528 bp, 217 bp. For detection of the rs731236 polymorphism, 745 bp PCR product was hydrolyzed overnight at 65 °C with TaqI restriction enzyme (Eurx, Poland). TaqI has two binding sites on the PCR product and produces a following fragments: TT (TT) 494, 251 bp; TC (Tt) 494, 293, 251, 201 bp and CC (tt) 293, 251, 201 bp. DNA fragments obtained after respective restrictive enzyme digestion and the DNA size marker were electrophoresed on a 2.5% agarose gel with Midori Green Advanced DNA Stain (Nippon Genetics, Europe GmbH). Description of the studied polymorphism genes is presented Table 1.Table 1 Primer sequences, location of the primer pairs, and fragment sizes of the vitamin D receptor gene polymorphisms. VDR polymorphism Location Primers Enzyme Product rs2228570 Exon 2 (chr12:47879112) 5′-AGCTGGCCCTGGCACTGACTCTGCTCT-3’ 5′-ATGGAAACACCTTGCTTCTTCTCCCTC-3’ FokI C (F): 267 bpT (f): 197 bp, 70 bp rs1544410 Intron 8 (chr12:47846052) 5′-CAACCAAGACTACAAGTACCGCGTCAGTGA-3’ 5′-AACCAGCGGGAAGAGGTCAAGGG-3’ BsmI G (b): 646 bp, 175 bp A (B): 821 bp rs7975232 Intron 8 (chr12:47845054) 5′-CAGAGCATGGACAGGGAGCAA-3' 5′-GCAACTCCTCATGGCTGAGGTCTC-3’ ApaI A (A): 745 bp C (a): 528 bp, 217 bp rs731236 Exon 9 (chr12:47844974) TaqI T (T): 494 bp, 251 bp C (t): 293 bp, 251 bp, 201 bp VDR polymorphisms: FokI (rs2228570); TaqI (rs731236); ApaI (rs7975232); BsmI (rs1544410); chr12—chromosome 12; Allels: C, T, G, A. Ethics statement All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of Poznan University of Medical Sciences (no. 66/14 and 799/16). Informed consent was obtained from all parents. Statistical analysis Statistical analysis was performed using CytelStudio version 11.1.0 (CytelStudio Software Corporation, Cambridge, Massachusetts, United States) and Statistica version 10 (Stat Soft, Inc., Tulsa, Oklahoma, United States). A p value of less than 0.05 indicates statistical significance. Categorical variables were presented as a percentage. Non-normally distributed continuous variables were tested by the Shapiro–Wilk test and showed as median and ranges. To evaluate the association between prematurity complications and categorical variables the following test were performed: the Fisher exact probability test, the Chi-square test, Fisher Freeman Halton, and Chi-squared test with Yates correction. U Mann–Whitney test was used to analyze differences in non-normally distributed continuous variables. Results Complications of prematurity IVH Table 2 presents demographic and clinical features of enrolled patients. Of the 114 infants, 55 (48.2%) developed IVH. The infants were diagnosed according to stages of IVH; 20 (36.4%) newborns were diagnosed with IVH stage I, 25 (45.5%) with IVH stage II, 10 (18.2%) with stage III and no neonates with stage IV. In our study population, male infants were significantly more likely to develop IVH stage II/III (26 (74.3%) male vs 9 (25.7%) female, p = 0.0251). Furthermore, the frequency of IVH stage II–IV was inversely correlated to gestational age [prevalence was higher in children born before 29 weeks of gestation as compared to those after 29 weeks of gestation (88.6% vs 11.4% respectively, p < 0.001)]. Incidence of IVH was also higher in newborns with birth weight less than 1000 g (77.1% vs 22.9%, p < 0.001), with lower Apgar scores in first (5.48 vs 3.6, p = 0.0001) and fifth minute of life (7.4 vs. 6.37, p = 0.001), as well as with intrauterine infection (85.7% vs 14.3%, p < 0.001). 9 of the 55 (11.4%) neonates with IVH died during hospitalization (p = 0.004).Table 2 Demographic and clinical characteristics of enrolled infants. Complications RDS IVH (II–IV) BPD NEC ROP Yes No p value Yes No p value Yes No p value Yes No p value Yes No p value Gender Male 63 4 0.7597a 26 41 0.0251e 23 44 0.8393e 16 51 0.8402e 27 40 0.8098e Female 44 3 9 38 17 30 12 35 20 27 Gestational age (week)  < 29 65 2 0.0953a 31 36  < 0.00001a 34 33 0.0001a 21 46 0.0446e 37 30 0.0003e  ≥ 29 42 5 4 43 6 41 7 40 10 37 Birth weight (g)  < 750 19 1 0.1129b 11 9 0.0001e 13 7  < 0.00001e 6 14 0.1134e 14 6 0.0033e 750–1000 34 0 16 18 18 16 12 22 16 18  > 1000 54 6 8 52 9 51 10 50 17 43 Apgar score 1st minute 5 (1–10) 6 (1–10) 0.5796c 4 (1–7) 6 (1–10) 0.0001c 4 (1–7) 6 (1–10) 0.0048c 5 (1–9) 6 (1–10) 0.4195c 4 (1–6) 6 (1–10) 0.028c 5th minute 7 (1–10) 7 (5–10) 0.9321c 7 (1–10) 7 (2–10) 0.001c 7 (1–10) 7 (4–10) 0.0029c 7 (5–10) 7 (1–10) 0.8434c 7 (4–9) 7 (1–10) 0.0951c Mode of delivery Vaginal 46 5 0.283a 19 32 0.1723e 20 31 0.406e 16 35 0.1285e 22 29 0.7095e Cesarean section 61 2 16 47 20 43 12 51 25 38 pH 7.32 (6.91–7.53) 7.29 (7.07–7.51) 0.5693c 7.29 (6.98–7.51) 7.33 (6.91–7.53) 0.2098c 7.34 (6.91–7.51) 7.31 (7.02–7.53) 0.5668c 7.37 (7.16–7.53) 7.31 (6.91–7.51) 0.0304c 7.31 (6.91–7.4) 7.32 (7–7.53) 0.31c BE − 2.6 (− 21.9 to 10.6) − 3.5 (− 9.4 to − 0.4) 0.2768c − 2.9 (− 16.9 to 0.8) − 2.8 (− 21.9 to 10.6) 0.4007c − 2.35 (− 21.9 to 2.3) − 3 (− 14.7 to 10.6) 0.5118c − 2.02 (− 9.9 to 2.8) − 3 (− 21.9 to 10.6) 0.1274c − 3.03 (− 21.9 to 0.7) − 2.85 (− 14.7 to 10.6) 0.2174c Intrauterine infection Yes 65 5 0.8716a 30 40 0.0008a 29 41 0.0736e 21 49 0.0889e 32 38 0.2197e No 42 2 5 39 11 33 7 37 15 29 In-born 98 6 0.4837d 31 73 0.7577a 38 66 0.484a 26 78 0.9731a 44 60 0.6753a Out-born 9 1 4 6 2 8 2 8 3 7 Deaths Yes 12 1 0.7143a 9 4 0.004a 0 13 0.0038d 6 7 0.1143a 0 13 0.0007d No 95 6 26 75 40 61 22 79 47 54 Dell Statistica(data analysis software system), version 10. software.dell.com. BPD bronchopulmonary dysplasia, IVH intraventricular hemorrhage, NEC necrotizing enterocolitis, RDS respiratory distress syndrome, ROP retinopathy of prematurity. aChi-square test with Yate's correction. bFisher Freeman Halton test. cMann Whitney test; dFisher's exact test; e Chi-square test. RDS RDS developed in 107/114 (93.9%) infants. No significant differences were observed in the clinical characteristics between the RDS and non-RDS infants, as seen in Table 2. BPD Furthermore, forty of the 114 infants (35.1%) suffered from BPD. Frequency of BPD was higher in children born before 29 weeks of gestation (85.0% vs 15.0%, p = 0.001). BPD incidence was also more pronounced in newborns with birth weight less than 1000 g (77.5% vs 22.5%, p < 0.001), or had lower Apgar scores in first (5.38 vs 4.03, p = 0.0048) and fifth minute of life (7.4 vs. 6.3; p = 0.0029). NEC Almost a quarter of the included infants developed NEC (28/114; 24.6%). The incidence of NEC was observed to be higher in children born before 29 weeks of gestation (75.0% vs 25.0%, p = 0.0446). ROP In the 47/114 (41.2%) infants who developed ROP, incidence was significantly higher in those with earlier gestation (78.7% in infants < 29 weeks of gestation as compared to 21.3% in those older, p < 0.001). Higher rate of ROP was also recorded in infants with birth weight less than 1000 g (63.8% vs 36.2%, p = 0.0033), and with lower Apgar score in the first minute (5.01 vs 4.11, p = 0.028). VDR polymorphisms and complications of prematurity Analysis showed higher prevalence of BPD in premature infants with the genotype CC ApaI (rs7975232) gene polymorphism [OR 3.845 (1.065–14.82); p = 0.038]. Furthermore, the study revealed that BPD and NEC were approximately two times more likely to occur in infants with the allele C of ApaI (rs7975232) [respectively: OR 2.111 (1.075–4.242), p = 0.028; and OR 2.129 (1.169–3.912), p < 0.05]. No other significant associations were found with the rest of the polymorphisms. Genotype and allele distribution in infants with complications of prematurity is presented in Table 3.Table 3 Genotype and allele distribution of infants with or without RDS, BPD, IVH, NEC or ROP. Polymorphism Complications RDS IVH (II–IV) NEC BPD ROP Yes No p value OR Yes No p value OR Yes No p value OR Yes No p value OR Yes No p value OR VDR FokI (rs2228570) Genotype  CC 33 3 References 10 26 References 6 30 References 12 24 References 15 21 References  CT 20 2 1 0.909 (0.095—11.78) 18 38 0.838 1.232 (0.451—3.489) 16 40 0.290 2 (0.640—6.963) 18 38 1 0.947 (0.357—2.57) 22 34 0.989 0.906 (0.356—2.328)  TT 54 2 0.596 2.455 (0.264—30.51) 7 15 0.967 1.213 (0.318—4.43) 6 16 0.521 1.875 (0.42—8.242) 10 12 0.518 1.667 (0.487—5.65) 10 12 0.99 1.167 (0.349—3.861) Allele  C 86 8 References 38 90 References 28 100 References 42 86 References 52 76 References  T 128 6 0.333 1.984 (0.579—7.179) 32 68 0.816 1.115 (0.607—2.038) 28 72 0.362 1.389 (0.724—2.66) 38 62 0.499 1.255 (0.699—2.248) 42 58 0.941 1.058 (0.601—1.862) VDR TaqI (rs731236) Genotype  CC 8 0 References 2 6 References 1 7 References 3 5 References 4 4 References  TC 57 5 1 0 (0—9.266) 17 45 1 1.133 (0.179—12.52) 12 50 1.000 1.68 (0.184—81.94) 16 46 0.747 0.579 (0.1—4.19) 22 40 0.667 0.55 (0.093—3.289)  TT 42 2 1 0 (0—30.55) 16 28 0.853 1.714 (0.262—19.14) 15 29 0.435 3.621 (0.394—173.9) 21 23 0.889 1.522 (0.257—10.93) 21 23 1 0.913 (0.149—5.583) Allele  C 73 5 References 21 57 References 14 64 References 22 56 References 30 48 References  T 141 9 1 1.073 (0.272—3.72) 49 101 0.461 1.317 (0.693—2.551) 42 108 0.127 1.778 (0.868—3.801) 58 92 0.153 1.605 (0.857—3.06) 64 86 0.64 1.191 (0.657—2.173) VDR ApaI (rs7975232) Genotype  AA 21 2 References 6 17 References 3 20 References 6 17 References 9 14 References  AC 53 5 1 1.01 (0.089—6.778) 16 42 1 1.079 (0.327 - 12 46 0.649 1.739 (0.403—10.57) 15 43 1 0.988 (0.297—3.644) 20 38 0.883 0.819 (0.273—2.552)  CC 33 0 0.329 - 13 20 0.457 1.842 (0.507—7.195) 13 20 0.059 4.333 (0.954—26.65) 19 14 0.038 3.845 (1.065—14.82) 18 15 0.388 1.867 (0.558—6.363) Allele  A 95 9 References 28 76 References 18 86 References 27 77 References 38 66 References  C 119 5 42 82 0.323 1.39 (0.757—2.572) 38 86 0.028 2.111 (1.075—4.242) 53 71 0.012 2.129 (1.169—3.912) 56 68 0.237 1.43 (0.812—2.528) VDR BsmI (rs1544410) Genotype  AA 18 1 References 5 14 References 3 16 References 6 13 References 9 10 References  GA 48 4 1 0.667 (0.013—7.393) 14 38 1 1.032 (0.279—4.346) 10 42 1.000 1.27 (0.275—8.069) 13 39 0.786 0.722 (0.202—2.819) 17 35 0.389 0.539 (0.163—1.824)  GG 41 2 1 1.139 (0.018—23.16) 16 27 0.593 1.659 (0.447—6.97) 15 28 0.217 2.857 (0.648 - 21 22 0.325 2.068 (0.588—7.851) 21 22 1 1.061 (0.314—3.609) Allele  A 84 6 References 24 66 References 16 74 References 25 65 References 35 55 References  G 130 8 0.997 1.161 (0.319—3.967) 46 92 0.358 1.375 (0.738—2.596) 40 98 0.075 1.888 (0.945—3.893) 55 83 0.083 1.723 (0.938—3.205) 59 79 0.659 1.174 (0.66—2.096) Results are expressed as absolute number of patients (percentage). The odds ratio (OR) and 95% confidence intervals (95% CI). CC denotes homozygosity for the C-encoded VDR FokI (rs2228570) polymorphism variant; TT homozygosity for the T-encoded VDR FokI (rs2228570) T polymorphism variant; CT heterozygosity for VDR FokI (rs2228570) polymorphism. CC denotes homozygosity for the C-encoded VDR TaqI (rs731236) polymorphism variant; TT homozygosity for the T-encoded VDR TaqI (rs731236) T polymorphism variant; CT heterozygosity for VDR TaqI (rs731236) polymorphism. AA denotes homozygosity for the A-encoded VDR ApaI (rs7975232) polymorphism variant; CC homozygosity for the C-encoded VDR ApaI (rs7975232) T polymorphism variant; AC heterozygosity for VDR ApaI (rs7975232) polymorphism. AA denotes homozygosity for the A-encoded VDR BsmI (rs1544410) polymorphism variant; GG homozygosity for the G-encoded VDR BsmI (rs1544410) T polymorphism variant; AG heterozygosity for VDR BsmI (rs1544410). Cytel Studio version 11.1.0 (January 05, 2016). VDR vvitamin D receptor, BPD bronchopulmonary dysplasia, IVH intraventricular hemorrhage, NEC necrotizing enterocolitis, RDS respiratory distress syndrome, ROP retinopathy of prematurity. Discussion Abnormalities in vitamin D levels have consistently been reported to produce adverse effects on human health and disease development29. A physiological response to vitamin D, is regulated by nuclear VDR and its resulting transcription cascade. The overall mechanism of the VDR protein revolves around its binding to the active form of vitamin D, producing a protein interaction with the retinoid X receptor, resulting in the regulation of transcription factors30. Such regulation mainly involves the process of mineral metabolism but has also been associated in the regulation of other metabolic pathways pertaining to embryological and immunological responses and development31. The subtle variations in the genetic makeup of VDR, also known as polymorphisms, have been linked to a wide array of diseases including metabolic, immunological, and multiple cancers32. Polymorphisms in the VDR gene have also been found to influence neonate development, and is being increasingly explored for its role and prognostic value in certain neonatal complications. Maternal and fetal VDR genotype variants may increase the risk for preterm births33. As prematurity carries risk for multiple complications34, understanding the role of VDR polymorphisms in such complications become essential for elaborate prognosis. To date, few preterm infant complications have been linked to such polymorphic changes. However, a majority of the preterm complications remain unassessed for their association with VDR polymorphisms. Respiratory distress syndrome RDS is a common complication in preterm children, as a result of underdeveloped lungs, which interferes with the absorption of appropriate levels of oxygen35. Glasgow and colleagues argued for the significance of vitamin D playing a role as a prophylactic for respiratory distress in preterm babies36. An evaluation of RDS in preterm infants found that high levels of vitamin D decreased the probability of RDS by a ratio of 3.34 times37. Both Vitamin D and the VDR receptor influence embryological and perinatal development. VDR TaqI (rs731236) polymorphism, CC and CT genotype has been associated with increased risk of developing RDS in preterm neonates38. The authors found that within a TaqI polymorphism, a CC genotype variance was equated with a 5.22 times increased risk in developing RDS, while a TaqI CT genotype variance was 3.26 times more likely present in preterm infants with RDS. The mechanisms involving the VDR polymorphism with RDS, to date, are not well understood. Within the results of our study, the genetic variability of the VDR gene did not alter the VDR receptor significantly enough in order to influence the incidence of RDS in preterm neonates. A most recent publication by Ustun et al. argue that VDR TaqI polymorphism did influence the incidence of RDS but the Fok1 polymorphism did not38. Our study does replicate the lack of Fok1 VDR polymorphism influence on the incidence of RDS but disputes that of the TaqI VDR polymorphism. These antithetical results reveal the importance of further investigation into the influence of VDR polymorphisms on RDS in order to deduce possible genetic risk factors. Intraventricular hemorrhage The pathogenesis of intraventricular hemorrhage, involves a multifactorial etiology, influenced by both environmental and genetic elements39,40. Crucial components observed in the pathological variations of IVH include alterations in venous and arterial cerebral blood flow, which have been associated with the fragility of the germinal matrix vasculature41–43. To date, the influence of Vitamin D on IVH in preterm infants is up for debate with little to no apparent investigation on its influence of the VDR gene. Elimination of the VDR receptor in knockout mice has revealed alterations in the vascular function of vascular endothelial cells44. With the absence of endothelial VDR receptors, Ni and colleagues found a reduction of endothelial nitric oxide synthase (eNOS) expression. Polymorphic changes in endothelial nitric oxide synthase, have been associated with a 3.4-fold increased risk of developing IVH in preterm infants45. According to the results of our study, VDR polymorphisms do not affect the incidence of IVH. The slight variations in the VDR genetic makeup do not appear to influence IVH incidence rates. To the authors' knowledge, no previous study analyzing a potential association between VDR polymorphisms and IVH was identified. It is worth noting, that observations of preterm infants in the German Neonatal Network, showed no detectable differences in incidence frequency of IVH in preterm neonates with high and low Vitamin D levels46. Considering the multifactorial nature of IVH, further investigation is required to deduce potential hallmarks of VDR polymorphisms and IVH interactions. Bronchopulmonary dysplasia Both animal and human studies have placed emphasis on the role of vitamin D in proper lung maturation47,48. Hypovitaminosis D has been established as a potential risk factor for improper lung regulation and respiratory morbidities, such as RDS and BPD49. As such, VDR gene polymorphisms may have slight, but meaningful, variations that mimic vitamin D abnormalities and lead to its consequent effect32. In the performed analysis, the VDR gene polymorphism rs7975232 (ApaI) was significantly associated with a higher incidence of BPD. Preterm infants with the receptor genotype CC ApaI (rs7975232) were roughly 4 times more likely to develop BPD, while the infants with the allele C of ApaI (rs7975232) were about twice as likely. This is in contrast to a mirror study performed in 2014 by Koroglu et al.50. The study analyzed the same VDR polymorphisms (FokI, BsmI, ApaI, TaqI) in 109 preterm infants (47 of which developed BPD), and concluded that only the FokI receptor polymorphism was associated with an increased frequency of the dysplasia. Such contrasting findings highlight the need for further research concerning VDR polymorphism association to BPD. Necrotizing enterocolitis In the pathogenesis of NEC, the transmembrane protein, toll-like receptor 4 (TLR4), and its cascading effect has been established as a possible key component51. Abnormalities within this signalling pathway in the intestines leads to an unregulated activation of nuclear factor-kappa B (NF-κB), that in turn increases the production of proinflammatory cytokines52,53. This sequence of events leads to tissue damage and eventual NEC. Vitamin D plays a protective role in the intestines by regulating TLR4, and a deficiency in this vitamin has been reported as a feature of preterm NEC infants54,55. Nonetheless, to the authors’ knowledge, no previous studies have explored the potential role of VDR polymorphisms in NEC. The results of our analysis show that preterm infants with the VDR allele C of ApaI (rs7975232) were twice as likely to develop NEC. Such a finding highlights the possible role of VDR genetic variation on the overall interaction between vitamin D and the TLR4 cascade. An increasing number of reports have placed emphasis on the genetic predisposition of preterm infants to NEC56–61. However, due to lack of extensive research and coherence of results, validating studies remain necessary to elucidate the relationship between gene variation and NEC62. Including VDR polymorphisms in future genetic studies may prove beneficial in understanding certain infants vulnerability to NEC. Retinopathy of prematurity Two phases for ROP pathogenesis are generally recognized. The first phase involves suppressed insulin-like growth factor-1 (IGF-1) and VEGF, due to a hyperoxic neonatal state, that leads to a disruption of retinal vascularization63. Eventually, the resulting hypoxic stress from improper vascularization of the retina, stimulates the production of excess angiogenic factors (VEGF, IGF-1) that lead to new abnormal blood vessel formation (second phase)64. In a study evaluating the relationship between vitamin D levels and ROP, Kabatas EU et al. found that infants with lower serum 25-hydroxy vitamin D were 1.14 times more likely to develop ROP65. They hypothesized that vitamin D deficiency may facilitate angiogenic conditions in the retina, reinforcing the development of ROP. Such a link is yet to be extensively explored. To the authors' knowledge, this is the first study analyzing a potential association between VDR polymorphism and ROP. The mild variations in the genetic makeup of the receptor did not appear to influence ROP incidence. Polymorphisms, particularly those relating to VEGF, have previously been highlighted as risk factors in ROP, underlining a possible genetic predisposition66–68. However, according to the results of our study, VDR polymorphisms remain inconsequential to ROP development, and require further investigation. In the presented study, the vitamin D levels in the preterm infants were not analysed for a possible correlation to the prematurity complications. The assessment protocols focused solely on the genetic background of these complications. Including such a variable in further analysis can assist in deconstructing the relationship between receptor polymorphisms and development of preterm complications. Notably, in recent years, alternative pathways of vitamin D activation have also been identified. Slominski AT and colleagues defined a novel pathway for metabolizing vitamin D3, revolving around the mitochondrial enzyme CYP11A1, and found predominantly in the adrenal glands, placenta, and keratinocytes of the epidermis69–71. Understanding the role of this novel pathway and its similar, yet distinct, vitamin D hydroxyderivatives (and its receptors) may further unveil some clinical relevance to preterm infants and their associated complications. In addition to varying pathways of vitamin D activation, different receptors for the active metabolite should also be taken into consideration for further analysis72. Receptors such as ROR (both α and γ) and AhR have shown interactions with varying vitamin D derivatives, underlining the misconception that VDR is the sole receptor for the vitamin73–75. Exploring the downstream influence of ROR and AhR gene polymorphisms, alongside VDR, allows for more elaborate understanding of this pivotal and versatile vitamin. Despite providing fundamental insight into the relationship between VDR polymorphisms and preterm infant complications, the above-mentioned genetic analysis acts as preliminary and requires further investigation. Larger sample sizes in non-homogenous populations can provide valuable information concerning patterns of pathogenesis and genetic susceptibility of certain infants. Allocating efforts and resources into the role of polymorphisms, including that of VDR, in preterm complications carry promising potential and can allow for future construction of more personalized care. Conclusion Exploring genetic variations in the vitamin D physiological pathway of functioning may broaden the current understanding of genetic susceptibility to preterm complications. The genotype CC of ApaI (rs7975232) VDR gene polymorphism was associated with a 3.8 times increase in likelihood of developing BPD in preterm infants. Furthermore, infants with the allele C of Apa I (rs7975232) were twice as likely to develop BPD and NEC. Including VDR polymorphisms in future genetic assessments of preterm complications is advised. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Author contributions K.K., D.S. designed research; K.K., D.S., S.R.A., L.M.K., collected and analysed the data, K.K., D.S., S.R.A., L.M.K., K.D., H.W., A.S-M., G.K., performed research; G.K. was responsible for PCR procedure. All authors commented on the manuscript at all grades. Competing interests The authors declare no competing interests. ==== Refs References 1. Kato S The function of vitamin d receptor in vitamin D action J. Biochem. 2000 127 717 722 10.1093/oxfordjournals.jbchem.a022662 10788778 2. Pike JW Meyer MB The vitamin d receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin d3 Endocrin. Metab. Clin. 2010 39 255 269 10.1016/j.ecl.2010.02.007 3. Knabl J Role of placental vdr expression and function in common late pregnancy disorders Int. J. Mol. Sci. 2017 18 2340 10.3390/ijms18112340 4. Bischoff-Ferrari HA Borchers M Gudat F Durmuller U Stahelin HB Dick W Vitamin d receptor expression in human muscle tissue decreases with age J. Bone Miner. Res. 2004 19 265 269 10.1359/jbmr.2004.19.2.265 14969396 5. Bikle DD Vitamin d metabolism, mechanism of action, and clinical applications Chem. Biol. 2014 21 319 329 10.1016/j.chembiol.2013.12.016 24529992 6. Taymans SE Pack S Pak E The human vitamin d receptor gene (vdr) is localized to region 12cen-q12 by fluorescent in situ hybridization and radiation hybrid mapping: genetic and physical vdr map J. Bone Min. Res. 1999 14 1163 1166 10.1359/jbmr.1999.14.7.1163 7. Mukhtar, M. et al. Vitamin d receptor gene polymorphism: an important predictor of arthritis development. BioMed Res. Int. 6, ID8326246 (2019). 8. Yu Z-H Chen M Zhang Q-Q Hu X The association of vitamin d receptor gene polymorphism with lung cancer risk: an update meta-analysis Comb. Chem. High T. Scr. 2018 21 704 710 9. Imani D Razi B Motallebnezhad M Rezaei R Association between vitamin d receptor (vdr) polymorphisms and the risk of multiple sclerosis (ms): an updated meta-analysis BMC Neurol. 2019 19 339 10.1186/s12883-019-1577-y 31878897 10. Apaydın M The vdr gene fokI polymorphism is associated with gestational diabetes mellitus in Turkish women BMC Med. Genet. 2019 20 82 10.1186/s12881-019-0820-0 31096931 11. Angel B The association of vdr polymorphisms and type 2 diabetes in older people living in community in Santiago de Chile Nutr. Diabetes. 2018 8 31 10.1038/s41387-018-0038-9 29795525 12. Han J-C Du J Zhang Y-J Vitamin d receptor polymorphisms may contribute to asthma risk J. Asthma. 2016 53 790 800 10.3109/02770903.2016.1158267 27088875 13. Laczmanski L Milewicz A Lwow F Vitamin d receptor gene polymorphism and cardiovascular risk variables in elderly Polish subjects Gunecol. Endocrinol. 2013 29 268 272 10.3109/09513590.2012.736562 14. Wu J Shang D-P Yang S Association between the vitamin d receptor gene polymorphism and osteoporosis Biomed. Rep. 2016 5 233 236 10.3892/br.2016.697 27446548 15. Gelder CM Hart KW Williams OM Vitamin d receptor gene polymorphisms and susceptibility to mycobacterium malmoense pulmonary disease J. Infect. Dis. 2000 181 2099 2102 10.1086/315489 10837203 16. weet, L. R., Keech, C., Klein, N. P. et al. Respiratory distress in the neonate: case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine. 35, 6506–17 (2017) 17. Sweet DG Carnielli V Greisen G European consensus guidelines on the management of respiratory distress syndrome: 2019 update Neonatology. 2019 115 432 450 10.1159/000499361 30974433 18. Papile LA Burstein J Burstein R Koffler H Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm J. Pediatr. 1978 92 529 534 10.1016/S0022-3476(78)80282-0 305471 19. Fischer HS Sustained inflations and avoiding mechanical ventilation to prevent death or bronchopulmonary dysplasia: a meta-analysis Eur. Respir. Rev. 2018 27 180083 10.1183/16000617.0083-2018 30487291 20. Nyman A Korhonen T Munck P Parkkola R Factors affecting the cognitive profile of 11-year-old children born very preterm Pediatr. Res. 2017 82 324 332 10.1038/pr.2017.64 28422947 21. Isayama T Lee SK Yang J Lee D Revisiting the definition of bronchopulmonary dysplasia effect of changing panoply of respiratory support for preterm neonates JAMA Pediatr. 2017 171 271 279 10.1001/jamapediatrics.2016.4141 28114678 22. Jensen EA Dysart K Gantz MG McDonald S Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network: the diagnosis of bronchopulmonary dysplasia in very preterm infants: an evidence-based approach Am. J. Respir. Crit. Care Med. 2019 200 751 759 10.1164/rccm.201812-2348OC 30995069 23. Jobe AH Bancalari E Bronchopulmonary dysplasia Am. J. Respir. Crit. Care Med. 2001 163 1723 1729 10.1164/ajrccm.163.7.2011060 11401896 24. Gregory KA DeForge CE Natale KM Necrotizing enterocolitis in the premature infant: neonatal nursing assessment, disease pathogenesis, and clinical presentation Adv. Neonatal Care. 2011 11 155 166 10.1097/ANC.0b013e31821baaf4 21730907 25. Rich BS Dolgin SE Necrotizing enterocolitis Pediatr. Rev. 2017 38 12 552 559 10.1542/pir.2017-0002 29196510 26. Gotz-Wieckowska A Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment Sci. Rep. 1997 7 11894 10.1038/s41598-017-12264-z 27. The International Classification of Retinopathy of Prematurity Revisited Arch. Ophthalmol 2005 123 991 999 10.1001/archopht.123.7.991 16009843 28. Gobel W Richard G Retinopathy of prematurity-current diagnosis and management Eur J. Pediatr. 1993 152 286 290 10.1007/BF01956734 8482272 29. Zhang R Naughton DP Vitamin d in health and disease: current perspectives Nutr. J. 2010 9 65 10.1186/1475-2891-9-65 21143872 30. Barsony J Prufer K Vitamin d receptor and retinoid x receptor interactions in motion Vitam. Horm. 2002 65 345 376 10.1016/S0083-6729(02)65071-X 12481554 31. Nair R Maseeh A Vitamin d: the “sunshine” vitamin J. Pharmacol. Pharmacother. 2012 3 118 126 22629085 32. Valdivielso JM Fernandez E Vitamin d receptor polymorphisms and diseases Clin. Chim. Acta. 2006 371 1 12 10.1016/j.cca.2006.02.016 16563362 33. Barchitta M Single nucleotide polymorphisms in vitamin d receptor gene affect birth weight and the risk of preterm birth: results from the “mamma & bambino” cohort and a meta-analysis Nutrients. 2018 10 1172 10.3390/nu10091172 34. Randis TM Complications associated with premature birth AMA J. Ethics. 2008 10 647 650 10.1001/virtualmentor.2008.10.10.cprl1-0810 35. Course C Chakraborty M Management of respiratory distress syndrome in preterm infants in wales: a full audit cycle of a quality improvement project Sci. Rep. 2020 10 3536 10.1038/s41598-020-60091-6 32103050 36. Glasgow JFT Thomas PS Rachitic respiratory distress in small preterm infants Arch. Dis. Child. 1977 52 268 273 10.1136/adc.52.4.268 860872 37. Ataseven F Aygun C Okuyucu A Is vitamin D deficiency a risk factor for respiratory distress syndrome? Int. J Vitam. Nutr. Res. 2013 83 232 237 10.1024/0300-9831/a000165 25008013 38. Ustun N Eyerci N Karadag N Association of vitamin d receptor gene FokI and TaqI polymorphisms and risk of RDS J. Matern. Fetal. Neonatal. Med. 2020 33 3640 3646 10.1080/14767058.2019.1582629 30760068 39. Ment LR Aden U Lin A Gene-environment interactions in severe intraventricular hemorrhage of preterm neonates Pediatr. Res. 2014 75 241 250 10.1038/pr.2013.195 24192699 40. Szpecht D Szymankiewicz M Seremak-Mrozikiewicz A Gadzinowski J The role of genetic factors in the pathogenesis of neonatal intraventricular hemorrhage Folia Neuropathol. 2015 53 1 7 10.5114/fn.2015.49968 25909869 41. Kenet G Kuperman AA Strauss T Brenner B Neonatal ivh: mechanisms and management Thromb Res. 2011 127 S120 S122 10.1016/S0049-3848(11)70032-9 21262430 42. Ballabh P Intraventricular hemorrhage in premature infants: Mechanism of disease Pediatr. Res. 2010 67 1 8 10.1203/PDR.0b013e3181c1b176 19816235 43. Ballabh P Pathogenesis and Prevention of Intraventricular Hemorrhage Clin. Perinatol. 2014 41 47 67 10.1016/j.clp.2013.09.007 24524446 44. Ni W Watts SW Ng M Elimination of vitamin d receptor in vascular endothelial cells alters vascular function Hypertension 2014 64 1290 1298 10.1161/HYPERTENSIONAHA.114.03971 25201890 45. Szpecht D Role of endothelial nitric oxide synthase and endothelin-1 polymorphism genes with the pathogenesis of intraventricular hemorrhage in preterm infants Sci Rep. 2017 7 42541 10.1038/srep42541 28211916 46. Mannhardt C Genetic predisposition for vitamin d deficiency is not associated with adverse outcome of very low birth weight infants: a cohort study from the german neonatal network PLoS ONE 2020 15 e0230426 10.1371/journal.pone.0230426 32231377 47. Zosky GR Berry LJ Elliot JG Vitamin d deficiency causes deficits in lung function and alters lung structure Am. J. Respir. Crit. Care Med. 2011 183 1336 1343 10.1164/rccm.201010-1596OC 21297070 48. Park S-H Association of vitamin d status at birth and respiratory outcomes in preterm infants Korean J. Pediatr. 2019 62 162 163 10.3345/kjp.2018.07311 30999725 49. Lykkedegn S Sorensen GL Beck-Nielsen SS Christesen HT The impact of vitamin d on fetal and neonatal lung maturation. A systematic review Am. J. Physiol. Lung Cell Mol. Physiol. 2015 308 L587 L602 10.1152/ajplung.00117.2014 25595644 50. Koroglu OA Onay H Cakmak B Association of vitamin d receptor gene polymorphisms and bronchopulmonary dysplasia Pediatr Res. 2014 76 171 176 10.1038/pr.2014.63 24796371 51. Tanner SM Berryhill TF Ellenburg JL Pathogenesis of necrotizing enterocolitis Am. J. Clin. Pathol. 2015 185 4 16 10.1016/j.ajpath.2014.08.028 52. Takeda K Akira S Roles of toll-like receptors in innate immune responses Genes Cells. 2001 6 733 742 10.1046/j.1365-2443.2001.00458.x 11554921 53. Palsson-McDermott EM O’Neill LAJ Signal transduction by the lipopolysaccharide receptor, toll-like receptor-4 Immunology 2004 113 153 162 10.1111/j.1365-2567.2004.01976.x 15379975 54. Shi Y Liu T Zhao X Vitamin d ameliorates neonatal necrotizing enterocolitis via suppressing TLR4 in a murine model Pediatr. Res. 2018 83 1024 1030 10.1038/pr.2017.329 29281615 55. Yang L-R Li H Zhang T Zhao R-C Relationship between vitamin d deficiency and necrotizing enterocolitis in preterm infants Zhongguo Dang Dai Er Ke Za Zhi 2018 20 178 183 29530115 56. Moonen RM Risk of necrotizing enterocolitis associated with the single nucleotide polymorphisms VEGF C-2578A, IL-18 C-607A, and IL-4 receptor α-chain A-1902G: a validation study in a prospective multicenter cohort Front. Pediatr. 2020 8 45 10.3389/fped.2020.00045 32133331 57. Szebeni B Szekeres R Rusai K Genetic polymorphisms of CD14, toll-like receptor 4, and caspase-recruitment domain 15 are not associated with necrotizing enterocolitis in very low birth weight infants J. Pediatr. Gastr. Nutr. 2006 42 27 31 10.1097/01.mpg.0000192246.47959.b2 58. Szpecht D Neumann-Klimasinska N Blaszczynski M Candidate gene analysis in pathogenesis of surgically and non-surgically treated necrotizing enterocolitis in preterm infants Mol. Cell. Biochem. 2018 439 53 63 10.1007/s11010-017-3135-5 28770467 59. Banyasz I Bokodi G Vasarhelyi B Genetic polymorphisms for vascular endothelial growth factor in perinatal complications Eur. Cytokine. Netw. 2006 17 266 270 17353160 60. Sankararaman S The prevalence of platelet activating factor acetylhydrolase single nucleotide polymorphisms in relationship to necrotizing enterocolitis in northwest louisiana infants Springerplus. 2013 2 294 10.1186/2193-1801-2-294 23888267 61. Sampath V Le M Lane L The NFKB1 (g-24519delATTG) variant is associated with necrotizing enterocolitis (NEC) in premature infants J. Surg. Res. 2011 169 e51 e57 10.1016/j.jss.2011.03.017 21529841 62. Cuna A George L Sampath V Genetic predisposition to necrotizing enterocolitis in premature infants: current knowledge, challenges, and future directions Semin. Fetal. Neonatal. Med. 2018 23 387 393 10.1016/j.siny.2018.08.006 30292709 63. Saugstad OD Oxygen and retinopathy of prematurity J. Perinatol. 2006 26 S46 S50 10.1038/sj.jp.7211475 16482198 64. Smith LEH Pathogenesis of retinopathy of prematurity Semin. Neonatol. 2003 8 469 473 10.1016/S1084-2756(03)00119-2 15001119 65. Kabatas EU Dinlen NF Zenciroglu A Relationship between serum 25-hydroxy vitamin D levels and retinopathy of prematurity Scott. Med. J. 2017 62 129 135 10.1177/0036933017701867 28899218 66. Banyasz I Bokodi G Vannay A Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity Curr. Eye Res. 2006 31 685 690 10.1080/02713680600801123 16877277 67. Ali AA Hussien NF Samy RM Husseiny KA Polymorphisms of vascular endothelial growth factor and retinopathy of prematurity J. Prediat. Ophth. Strab. 2015 52 245 253 10.3928/01913913-20150506-02 68. Lei X-J Zhao Y-X Qiao T Influence of polymorphisms in VEGF, ACE, TNF and GST genes on the susceptibility to retinopathy of prematurity among Chinese infants Int. J. Ophthalmol. 2018 11 1451 1457 30225217 69. Slominski AT Kim T-K Shehabi HZ In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1 FASEB J. 2012 26 9 3901 3915 10.1096/fj.12-208975 22683847 70. Slominski AT Li W Kim T-K Novel activities of CYP11A1 and their potential physiological significance J. Steroid Biochem. Mol. Biol. 2015 151 25 37 10.1016/j.jsbmb.2014.11.010 25448732 71. Slominski AT Kim T-K Li W Detection of novel CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland Sci. Rep. 2015 5 1 14875 10.1038/srep14875 26445902 72. Slominski AT Chaiprasongsuk A Janjetovic Z Photoprotective properties of vitamin D and lumisterol hydroxyderivatives Cell Biochem. Biophys. 2020 78 2 165 180 10.1007/s12013-020-00913-6 32441029 73. Slominski AT Kim T-K Hobrath JV Endogenously produced nonclassical vitamin D hydroxy-metabolites act as “biased” agonists on VDR and inverse agonists on RORα and RORγ J. Steroid Biochem. Mol. Biol. 2017 173 42 56 10.1016/j.jsbmb.2016.09.024 27693422 74. Slominski AT Kim T-K Takeda Y RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D FASEB J. 2014 28 7 2775 2789 10.1096/fj.13-242040 24668754 75. Slominski AT Kim T-K Janjetovic Z Differential and overlapping effects of 20,23(OH)2D3 and 1,25(OH)2D3 on gene expression in human epidermal keratinocytes: identification of AhR as an alternative receptor for 20,23(OH)2D3 Int. J. Mol. Sci. 2018 19 10 3072 10.3390/ijms19103072